Lance

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Retrieved on: 
星期一, 四月 29, 2024
FDA, FIX, Lance, Food, Bleeding, Disease, Patient safety, Factor IX, Patient, Physician, CDX, Haemophilia, Pharmaceutical industry

BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.

Key Points: 
  • The nAbCyte cell-based neutralizing antibody assay is a component of Pfizer's program to target recombinant adeno-associated virus (rAAV)-based gene therapies to the appropriate patient population.
  • "We believe this companion diagnostic is an important tool for evaluating patients who may be suitable for gene therapy as the treatment paradigm advances with the introduction of gene therapies like BEQVEZ."
  • A negative test result indicates that an individual with moderate to severe hemophilia B can be considered for BEQVEZ therapy.
  • The FDA approval of nAbCyte Anti-AAVRh74var HB-FE CDx builds on Labcorp's comprehensive cell and gene therapy solutions, including specialized pre-clinical toxicology, biomarker and CDx development, and post-commercialization capabilities.

Blue Lake Biotechnology Reports Positive Interim Clinical Data in Children for Its RSV Vaccine Candidate

Retrieved on: 
星期四, 三月 21, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Immune system, RSV, Vaccine, Infection, Lance, Immunoglobulin A, NAB, Safety

The data show that BLB201 is immunogenic and well tolerated, with no significant safety events reported to date following a single intranasal dose in RSV seropositive children 18-59 months of age.

Key Points: 
  • The data show that BLB201 is immunogenic and well tolerated, with no significant safety events reported to date following a single intranasal dose in RSV seropositive children 18-59 months of age.
  • The ongoing trial is currently enrolling both RSV seropositive and RSV seronegative children as young as eight months of age.
  • “Given the challenges of developing an RSV vaccine for children, it is highly encouraging that BLB201, our intranasal RSV vaccine candidate, has been well tolerated in this age group so far,” said Biao He, Ph.D., founder and CEO of Blue Lake Biotechnology.
  • “It is also very exciting to see RSV-specific immune responses to our vaccine in children who have previously been exposed to RSV.

Carpenter & Zuckerman Appoints Two New Partners and Five New Senior Attorneys from Among its Ranks

Retrieved on: 
星期五, 一月 26, 2024
Lawyer, Personal injury, Accident, Lance, Behringer, Growth

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Carpenter & Zuckerman (CZ Law) announced today that senior trial lawyers, Lance Behringer and Benjamin Berkley , have been elected as the firm's newest partners.

Key Points: 
  • LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Carpenter & Zuckerman (CZ Law) announced today that senior trial lawyers, Lance Behringer and Benjamin Berkley , have been elected as the firm's newest partners.
  • Additionally, CZ Law has appointed five attorneys to the role of senior counsel, effective immediately.
  • "These attorneys have shown exemplary commitment to the firm's clients, the practice of personal injury law, and the firm as a whole," says Paul Zuckerman, Founding Partner of CZ Law.
  • Lance Behringer is a seasoned personal injury attorney and has successfully taken on some of the biggest cases in the nation.

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

Retrieved on: 
星期二, 十二月 12, 2023
MF59, Fever, Șaeș, RSV, Aes, Respiratory syncytial virus, Vaccine, Human, Ageing, Lance, Vaccination, Myalgia, CSL, VLP, Safety, Infection

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

Key Points: 
  • “We’re delighted to announce positive topline interim data from our Phase 2 trial of IVX-A12, our potential first-in-class combination vaccine candidate against RSV and hMPV,” said Adam Simpson, Chief Executive Officer of Icosavax.
  • The trial enrolled 264 healthy older adults aged 60 to 85 years, of which 241 subjects were evaluable for immunogenicity.
  • Topline interim safety and immunogenicity data from this trial were generally consistent with the previously reported Phase 1 data for IVX-A12.
  • IVX-A12 induced robust immune responses against both RSV and hMPV at Day 28 across both formulations with and without adjuvant.

Michael Baker International Names Lance Chimka Business Developer for the Pittsburgh Office

Retrieved on: 
星期一, 十二月 11, 2023
Carnegie Mellon University, Public policy, Engineering, Economic development, Allegheny County Airport, Lance, Economy, Region, Business administration, Office, Community, Allegheny County Airport Authority, Catholic University of America, Catholic higher education, Business

PITTSBURGH, Dec. 11, 2023 /PRNewswire/ -- Michael Baker International, a global leader in engineering, planning and consulting services, announced today that Lance Chimka has been named Business Developer for the Pittsburgh office. In this role, Mr. Chimka will be responsible for facilitating the firm's business development process to win new work by strengthening and expanding Michael Baker's client and industry relationships throughout western Pennsylvania.

Key Points: 
  • PITTSBURGH, Dec. 11, 2023 /PRNewswire/ -- Michael Baker International , a global leader in engineering, planning and consulting services, announced today that Lance Chimka has been named Business Developer for the Pittsburgh office.
  • In this role, Mr. Chimka will be responsible for facilitating the firm's business development process to win new work by strengthening and expanding Michael Baker's client and industry relationships throughout western Pennsylvania.
  • "For more than 80 years, Michael Baker has consistently delivered projects with a legacy of expertise, experience, innovation and integrity," said John Robinson, Office Executive – Pittsburgh at Michael Baker International.
  • "As we continue to Reimagine Michael Baker and extend this legacy, Lance will accelerate our firm's growth by partnering with operations leaders to generate and capture new business opportunities and enhance our firm's client and industry engagement.

How to Spoof Monster Hunter Now for New Weapons in December Update

Retrieved on: 
星期四, 十二月 7, 2023
GPX, Sleep, Movement, Weapon, Dual Blades, Monster Hunter, Monster, GPS, IOS, Hunting, Satellite navigation device, Video game, Lance

It can spoof the game and Monster Hunter new weapons unlock from the new update with zero downtime," says a PoGoskill spokesperson.

Key Points: 
  • It can spoof the game and Monster Hunter new weapons unlock from the new update with zero downtime," says a PoGoskill spokesperson.
  • So, what's new in the December update, and how do you spoof Monster Hunter Now without moving with PoGoskill?
  • The latest Monster Hunter update offers a particular quest featuring all monsters in Monster Hunter Now: Zinogre (Thunder), Barioth (Ice), Banbaro (Ice), and Radobaan (Sleep).
  • The December Monster Hunter Now weapons update includes two cool weapons.

Best Monster Hunter Now Spoofing and Joystick Tutorial from UltFone

Retrieved on: 
星期三, 十二月 6, 2023
Weapon, Android, The Anti-Detective, GPS, Map, Prison escape, Monster, IOS, Walking, Lance, Satellite navigation device, Hunting, Video game, Mobile phone

While the MH Now players are super excited about the update, there's one major concern: Will Monster Hunter Now spoofing be possible after the update?

Key Points: 
  • While the MH Now players are super excited about the update, there's one major concern: Will Monster Hunter Now spoofing be possible after the update?
  • However, there are certain precautions that you must keep in consideration for Monster Hunter Now GPS spoofing:
    Always use a reliable Monster Hunter Now fake GPS app.
  • Monster Hunter Now Joystick Feature: This tool has a Monster Hunter Now hack for walking using the joystick feature.
  • Here is the Monster Hunter Now spoofing tutorial using UltFone Location Changer:
    Download and install UltFone Location Changer on your computer.

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
星期三, 八月 9, 2023
KRAS, Chemistry, Congress, Lance, Patient, SLATE, Collaboration, Infection, Maintenance, Monitoring, Vaccination, Gritstone bio, Immunity, Research, Melinda French Gates, Gilead, ECCMID, CORAL, NCI, Vaccine, DNA, AACR, COVID-19, African, Cancer, NAB, Immunotherapy, Messenger, Government, Friends, National Cancer Institute, Bill & Melinda Gates Foundation, European, NIAID, Partnership, Circulating tumor DNA, Drug development, CRC, HIV, CMC, Clinical trial, Nature Communications, PCV, Cryptocurrency, Pharmaceutical industry, Neoplasm, Gritstone

EMERYVILLE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Molecular response, or reduction in ctDNA, is the primary efficacy endpoint for the Phase 2 portion of the GRANITE trial.
  • Gritstone delivered multiple presentations detailing advances in neoantigen prediction capabilities and cancer vaccine programs at the 2023 American Association for Cancer Research (AACR 2023, in April 2023).
  • Gritstone expects to initiate a randomized Phase 2 clinical trial within SLATE (“off-the-shelf” neoantigen vaccine program) in 2024.
  • Gritstone expects to share additional data from the CORAL-CEPI and CORAL-BOOST studies in Fall 2023.

CO-FOUNDERS OF FUTUREVERSE LAUNCH $50 MILLION FUND AND VENTURE STUDIO "BORN READY"

Retrieved on: 
星期四, 八月 3, 2023
Rolling Stone Australia, Scrubs (season 5), Blockchain, ABG, Partnership, NFT, Women in music, Internet, Wimbledon, Microsoft, Macdonald, Ripple Labs, Cat, Organization, McDonald & Co., The Co Founder, Investment, Rob Senderoff, Mastercard, Authentic Brands Group, AI, Polemos, Lance, Woman, C T Holdings, Death Row Records, Billboard, Adidas, Cryptocurrency, Futureversity, Centrality, Music

LOS ANGELES, Aug. 3, 2023 /PRNewswire/ -- Futureverse Co-Founders, Shara Senderoff and Aaron McDonald, announce today the launch of Born Ready, a new $50 million venture fund and studio. The fund's primary focus is to accelerate the development and adoption of emerging technology ventures that hold strategic collaboration potential with Futureverse or The Root Network, a public decentralized blockchain network optimized for metaverse apps and experiences.

Key Points: 
  • LOS ANGELES, Aug. 3, 2023 /PRNewswire/ -- Futureverse Co-Founders, Shara Senderoff and Aaron McDonald, announce today the launch of Born Ready , a new $50 million venture fund and studio.
  • Experienced and respected multi-hyphen venture capitalist-operator-entrepreneurs Senderoff and McDonald co-founded Futureverse together, along with Daniel Gillespie and Marco Brondani who also join Born Ready as partners.
  • Futureverse is a leading AI and metaverse technology and content company that recently announced a $54 million Series A funding round led by 10T Holdings, including contribution from Ripple Labs.
  • Shara previously co-founded Raised in Space, a blockchain focused investment fund, in partnership with music-mogul Scooter Braun and blockchain leader Ripple.

Union Pacific Appoints Jim Vena Chief Executive Officer

Retrieved on: 
星期三, 七月 26, 2023
Workforce, Union Pacific Corporation, Union Pacific Railroad, Marketing, Railroad Labor Board, Culture, Lance, UNP, Government, McCarthy, NYSE, Safety, Canadian National Railway, Management

OMAHA, Neb., July 26, 2023 /PRNewswire/ -- Union Pacific Corporation (NYSE: UNP) today announced Jim Vena has been appointed as chief executive officer and a member of the Board, effective August 14, 2023.

Key Points: 
  • OMAHA, Neb., July 26, 2023 /PRNewswire/ -- Union Pacific Corporation (NYSE: UNP) today announced Jim Vena has been appointed as chief executive officer and a member of the Board, effective August 14, 2023.
  • The company also announced that Beth Whited, Union Pacific's executive vice president, sustainability and strategy and chief human resources officer, has been appointed as president, reporting to Vena.
  • Vena succeeds Lance Fritz, who is stepping down as chairman, president and chief executive officer.
  • Vena has more than 40 years of industry experience and is returning to Union Pacific after serving as its chief operating officer from 2019-2020 and as a senior advisor to the chairman in 2021.